Rodryg Ramlau

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Frances A. Shepherd, Janet Dancey, Rodryg Ramlau et al. · Journal of Clinical Oncology · 2000 · 2.2K citations

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

Jean‐Yves Douillard, Rafael Rosell, Mario De Lena et al. · The Lancet Oncology · 2006 · 1.6K citations

Surgical Oncology, Cisplatin Versus Observation, Medicine +10

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Martin Reck, Joachim von Pawel, Petr Zatloukal et al. · Journal of Clinical Oncology · 2009 · 1.5K citations

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna et al. · The Lancet · 2009 · 1.4K citations · Full text

Medicine, Metronomic Therapy, Phase Iii Trial +7